Alteration of Endothelins: A Common Pathogenetic Mechanism in Chronic Diabetic Complications

Endothelin (ET) peptides perform several physiological, vascular, and nonvascular functions and are widely distributed in a number of tissues. They are altered in several disease processes including diabetes. Alteration of ETs have been demonstrated in organs of chronic diabetic complications in bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakrabarti, Subrata, Khan, Zia Ali, Cukiernik, Mark, Fukuda, Gen, Chen, Shali, Mukherjee, Suranjana
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2002
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2478589/
https://www.ncbi.nlm.nih.gov/pubmed/12546275
http://dx.doi.org/10.1080/15604280214939
Descripción
Sumario:Endothelin (ET) peptides perform several physiological, vascular, and nonvascular functions and are widely distributed in a number of tissues. They are altered in several disease processes including diabetes. Alteration of ETs have been demonstrated in organs of chronic diabetic complications in both experimental and clinical studies. The majority of the effects of ET alteration in diabetes are due to altered vascular function. Furthermore, ET antagonists have been shown to prevent structural and functional changes induced by diabetes in animal models. This review discusses the contribution of ETs in the pathogenesis and the potential role of ET antagonism in the treatment of chronic diabetic complications.

Ejemplares similares